Kite public offering looks to raise $350m for CAR T cell therapy support – BioPharma-Reporter.com
BioPharma-Reporter.com |
Kite public offering looks to raise $350m for CAR T cell therapy support
BioPharma-Reporter.com “We intend to use the net proceeds from this offering to support commercialization activities of axicabtagene ciloleucel, if approved, to support clinical activities related to KTE-C19 and our other CAR– and TCR-based product candidates,” the firm said … |
